Use of specific neuromodulators in the treatment of chronic, idiopathic cough: a systematic review.

Published

Journal Article (Review)

OBJECTIVE: The goal of this systematic review was to examine the evidence for the use of the neuromodulating agents, amitriptyline, gabapentin, pregabalin, and baclofen, in the management of chronic, idiopathic cough patients. DATA SOURCES: Online databases, including PubMed, Embase, Cochrane Review, and Web of Science, and publications cited in bibliographies were used. REVIEW METHODS: Literature was searched by the 2 authors with a priori criteria for study selection. RESULTS: Eight relevant articles were identified, including 2 randomized controlled trials, 2 prospective cohort or case-series designs with consecutive patients, 1 retrospective case series of consecutive patients, 1 retrospective case series whose consecutive status was not known, and 2 case reports of 6 and 2 patients, respectively. Improvements in cough-specific quality of life were noted in the randomized controlled trials. Cough severity was reduced in studies that measured this outcome measure. In the remaining studies, cough symptoms were less after neuromodulator treatment. CONCLUSION: Benefit from neuromodulator treatment with amitriptyline, gabapentin, pregabalin, and baclofen in chronic, idiopathic cough patients was demonstrated. Further investigations using objective and subjective outcome measures are needed as well as studies exploring optimal dose, length of treatment, and relapse rates posttreatment.

Full Text

Duke Authors

Cited Authors

  • Cohen, SM; Misono, S

Published Date

  • March 2013

Published In

Volume / Issue

  • 148 / 3

Start / End Page

  • 374 - 382

PubMed ID

  • 23300226

Pubmed Central ID

  • 23300226

Electronic International Standard Serial Number (EISSN)

  • 1097-6817

Digital Object Identifier (DOI)

  • 10.1177/0194599812471817

Language

  • eng

Conference Location

  • England